Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: Toxicity, pharmacokinetic, and biomarker evaluations

Julia A. Lawrence, Peter C. Adamson, Rafael Caruso, Catherine Chow, David Kleiner, Robert F. Murphy, David J. Venzon, Margaret Shovlin, Marianne Noone, Maria Merino, Kenneth H. Cowan, Muriel Kaiser, Joyce O'Shaughnessy, Jo Anne Zujewski

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Purpose: To determine the overall and dose-limiting toxicities (DLTs) of alitretinoin (9-cis-retinoic acid) in combination with tamoxifen and the pharmacokinetics of alitretinoin alone and when combined with tamoxifen in patients with metastatic breast cancer. The effect of tamoxifen and alitretinoin on MIB-1, a marker of proliferation, in unaffected breast tissue was explored. Patients and Methods: Eligible patients had metastatic breast cancer. Previous tamoxifen therapy was allowed. Planned dose levels for alitretinoin ranged from 50 to 140 mg/m2/d with 20 mg/d tamoxifen in all patients after 4 weeks of alitretinoin as a single agent. Plasma concentrations of alitretinoin and retinol were measured at baseline and after 1, 2, and 3 months. Breast core biopsies were obtained at baseline and after 2 months of therapy. Results: Twelve patients with metastatic breast cancer received a total of 86 cycles of therapy. At 90 mg/m2/d, three of five patients experienced a DLT: grade 3 headache, grade 3 hypercalcemia, and grade 3 noncardiogenic pulmonary edema. At 70 mg/m2/d, one of six patients experienced a DLT (headache), and this level was considered the maximal tolerated dose in this study. Three toxicities occurred that had not been reported previously with alitretinoin: an asymptomatic delay in dark adaptation, a marked decrease in high-density lipoprotein cholesterol, and the occurrence of enthesopathy. Two of the nine assessable patients had a durable clinical response: one partial response and stable disease for 18 months and one complete response in continuous remission for 48+ months. Both responding patients were estrogen receptor-positive and had previous tamoxifen therapy. There was a high degree of interpatient variability of plasma alitretinoin concentrations, although a significant decline in alitretinoin plasma levels over time was observed. MIB-1 scores declined in four of the eight paired breast specimens obtained. Conclusion: The combination of tamoxifen and alitretinoin is well tolerated and has antitumor activity in metastatic breast cancer. The recommended phase II dose is 70 mg/m2/d with 20 mg/d tamoxifen.

Original languageEnglish (US)
Pages (from-to)2754-2763
Number of pages10
JournalJournal of Clinical Oncology
Volume19
Issue number10
DOIs
StatePublished - May 15 2001

Fingerprint

Clinical Trials, Phase I
Tamoxifen
Pharmacokinetics
Biomarkers
Breast Neoplasms
Breast
Headache
alitretinoin
Dark Adaptation
Maximum Tolerated Dose
Hypercalcemia
Pulmonary Edema
Therapeutics
Vitamin A
Estrogen Receptors
HDL Cholesterol

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients : Toxicity, pharmacokinetic, and biomarker evaluations. / Lawrence, Julia A.; Adamson, Peter C.; Caruso, Rafael; Chow, Catherine; Kleiner, David; Murphy, Robert F.; Venzon, David J.; Shovlin, Margaret; Noone, Marianne; Merino, Maria; Cowan, Kenneth H.; Kaiser, Muriel; O'Shaughnessy, Joyce; Zujewski, Jo Anne.

In: Journal of Clinical Oncology, Vol. 19, No. 10, 15.05.2001, p. 2754-2763.

Research output: Contribution to journalArticle

Lawrence, JA, Adamson, PC, Caruso, R, Chow, C, Kleiner, D, Murphy, RF, Venzon, DJ, Shovlin, M, Noone, M, Merino, M, Cowan, KH, Kaiser, M, O'Shaughnessy, J & Zujewski, JA 2001, 'Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: Toxicity, pharmacokinetic, and biomarker evaluations', Journal of Clinical Oncology, vol. 19, no. 10, pp. 2754-2763. https://doi.org/10.1200/JCO.2001.19.10.2754
Lawrence, Julia A. ; Adamson, Peter C. ; Caruso, Rafael ; Chow, Catherine ; Kleiner, David ; Murphy, Robert F. ; Venzon, David J. ; Shovlin, Margaret ; Noone, Marianne ; Merino, Maria ; Cowan, Kenneth H. ; Kaiser, Muriel ; O'Shaughnessy, Joyce ; Zujewski, Jo Anne. / Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients : Toxicity, pharmacokinetic, and biomarker evaluations. In: Journal of Clinical Oncology. 2001 ; Vol. 19, No. 10. pp. 2754-2763.
@article{5952106c7af347ff815af75c463dca6b,
title = "Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: Toxicity, pharmacokinetic, and biomarker evaluations",
abstract = "Purpose: To determine the overall and dose-limiting toxicities (DLTs) of alitretinoin (9-cis-retinoic acid) in combination with tamoxifen and the pharmacokinetics of alitretinoin alone and when combined with tamoxifen in patients with metastatic breast cancer. The effect of tamoxifen and alitretinoin on MIB-1, a marker of proliferation, in unaffected breast tissue was explored. Patients and Methods: Eligible patients had metastatic breast cancer. Previous tamoxifen therapy was allowed. Planned dose levels for alitretinoin ranged from 50 to 140 mg/m2/d with 20 mg/d tamoxifen in all patients after 4 weeks of alitretinoin as a single agent. Plasma concentrations of alitretinoin and retinol were measured at baseline and after 1, 2, and 3 months. Breast core biopsies were obtained at baseline and after 2 months of therapy. Results: Twelve patients with metastatic breast cancer received a total of 86 cycles of therapy. At 90 mg/m2/d, three of five patients experienced a DLT: grade 3 headache, grade 3 hypercalcemia, and grade 3 noncardiogenic pulmonary edema. At 70 mg/m2/d, one of six patients experienced a DLT (headache), and this level was considered the maximal tolerated dose in this study. Three toxicities occurred that had not been reported previously with alitretinoin: an asymptomatic delay in dark adaptation, a marked decrease in high-density lipoprotein cholesterol, and the occurrence of enthesopathy. Two of the nine assessable patients had a durable clinical response: one partial response and stable disease for 18 months and one complete response in continuous remission for 48+ months. Both responding patients were estrogen receptor-positive and had previous tamoxifen therapy. There was a high degree of interpatient variability of plasma alitretinoin concentrations, although a significant decline in alitretinoin plasma levels over time was observed. MIB-1 scores declined in four of the eight paired breast specimens obtained. Conclusion: The combination of tamoxifen and alitretinoin is well tolerated and has antitumor activity in metastatic breast cancer. The recommended phase II dose is 70 mg/m2/d with 20 mg/d tamoxifen.",
author = "Lawrence, {Julia A.} and Adamson, {Peter C.} and Rafael Caruso and Catherine Chow and David Kleiner and Murphy, {Robert F.} and Venzon, {David J.} and Margaret Shovlin and Marianne Noone and Maria Merino and Cowan, {Kenneth H.} and Muriel Kaiser and Joyce O'Shaughnessy and Zujewski, {Jo Anne}",
year = "2001",
month = "5",
day = "15",
doi = "10.1200/JCO.2001.19.10.2754",
language = "English (US)",
volume = "19",
pages = "2754--2763",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "10",

}

TY - JOUR

T1 - Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients

T2 - Toxicity, pharmacokinetic, and biomarker evaluations

AU - Lawrence, Julia A.

AU - Adamson, Peter C.

AU - Caruso, Rafael

AU - Chow, Catherine

AU - Kleiner, David

AU - Murphy, Robert F.

AU - Venzon, David J.

AU - Shovlin, Margaret

AU - Noone, Marianne

AU - Merino, Maria

AU - Cowan, Kenneth H.

AU - Kaiser, Muriel

AU - O'Shaughnessy, Joyce

AU - Zujewski, Jo Anne

PY - 2001/5/15

Y1 - 2001/5/15

N2 - Purpose: To determine the overall and dose-limiting toxicities (DLTs) of alitretinoin (9-cis-retinoic acid) in combination with tamoxifen and the pharmacokinetics of alitretinoin alone and when combined with tamoxifen in patients with metastatic breast cancer. The effect of tamoxifen and alitretinoin on MIB-1, a marker of proliferation, in unaffected breast tissue was explored. Patients and Methods: Eligible patients had metastatic breast cancer. Previous tamoxifen therapy was allowed. Planned dose levels for alitretinoin ranged from 50 to 140 mg/m2/d with 20 mg/d tamoxifen in all patients after 4 weeks of alitretinoin as a single agent. Plasma concentrations of alitretinoin and retinol were measured at baseline and after 1, 2, and 3 months. Breast core biopsies were obtained at baseline and after 2 months of therapy. Results: Twelve patients with metastatic breast cancer received a total of 86 cycles of therapy. At 90 mg/m2/d, three of five patients experienced a DLT: grade 3 headache, grade 3 hypercalcemia, and grade 3 noncardiogenic pulmonary edema. At 70 mg/m2/d, one of six patients experienced a DLT (headache), and this level was considered the maximal tolerated dose in this study. Three toxicities occurred that had not been reported previously with alitretinoin: an asymptomatic delay in dark adaptation, a marked decrease in high-density lipoprotein cholesterol, and the occurrence of enthesopathy. Two of the nine assessable patients had a durable clinical response: one partial response and stable disease for 18 months and one complete response in continuous remission for 48+ months. Both responding patients were estrogen receptor-positive and had previous tamoxifen therapy. There was a high degree of interpatient variability of plasma alitretinoin concentrations, although a significant decline in alitretinoin plasma levels over time was observed. MIB-1 scores declined in four of the eight paired breast specimens obtained. Conclusion: The combination of tamoxifen and alitretinoin is well tolerated and has antitumor activity in metastatic breast cancer. The recommended phase II dose is 70 mg/m2/d with 20 mg/d tamoxifen.

AB - Purpose: To determine the overall and dose-limiting toxicities (DLTs) of alitretinoin (9-cis-retinoic acid) in combination with tamoxifen and the pharmacokinetics of alitretinoin alone and when combined with tamoxifen in patients with metastatic breast cancer. The effect of tamoxifen and alitretinoin on MIB-1, a marker of proliferation, in unaffected breast tissue was explored. Patients and Methods: Eligible patients had metastatic breast cancer. Previous tamoxifen therapy was allowed. Planned dose levels for alitretinoin ranged from 50 to 140 mg/m2/d with 20 mg/d tamoxifen in all patients after 4 weeks of alitretinoin as a single agent. Plasma concentrations of alitretinoin and retinol were measured at baseline and after 1, 2, and 3 months. Breast core biopsies were obtained at baseline and after 2 months of therapy. Results: Twelve patients with metastatic breast cancer received a total of 86 cycles of therapy. At 90 mg/m2/d, three of five patients experienced a DLT: grade 3 headache, grade 3 hypercalcemia, and grade 3 noncardiogenic pulmonary edema. At 70 mg/m2/d, one of six patients experienced a DLT (headache), and this level was considered the maximal tolerated dose in this study. Three toxicities occurred that had not been reported previously with alitretinoin: an asymptomatic delay in dark adaptation, a marked decrease in high-density lipoprotein cholesterol, and the occurrence of enthesopathy. Two of the nine assessable patients had a durable clinical response: one partial response and stable disease for 18 months and one complete response in continuous remission for 48+ months. Both responding patients were estrogen receptor-positive and had previous tamoxifen therapy. There was a high degree of interpatient variability of plasma alitretinoin concentrations, although a significant decline in alitretinoin plasma levels over time was observed. MIB-1 scores declined in four of the eight paired breast specimens obtained. Conclusion: The combination of tamoxifen and alitretinoin is well tolerated and has antitumor activity in metastatic breast cancer. The recommended phase II dose is 70 mg/m2/d with 20 mg/d tamoxifen.

UR - http://www.scopus.com/inward/record.url?scp=19244371699&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19244371699&partnerID=8YFLogxK

U2 - 10.1200/JCO.2001.19.10.2754

DO - 10.1200/JCO.2001.19.10.2754

M3 - Article

C2 - 11352969

AN - SCOPUS:19244371699

VL - 19

SP - 2754

EP - 2763

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 10

ER -